NCT06576752 Management of Patients With Heart Failure at Home After Hospital Discharge
| NCT ID | NCT06576752 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Akershus |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 450 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 450 participants in total. It began in 2024-10-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess whether patients with acute heart failure (HF) can achieve the same level of HF-therapies by digital follow-up at home as compared to hospital visits according to the STRONG-HF strategy. Patients admitted to hospital with acute HF will be enrolled and randomized to either follow-up at the hospital out-patient clinic or digital follow-up at home.
Eligibility Criteria
Inclusion Criteria: * Hospital admission within the 72 hours prior to screening for acute HF. * NT-proBNP ≥ 1,000 pg/mL measured during the hospitalization * Systolic blood pressure ≥ 100 mmHg and of heart rate ≥ 60 bpm within 24 hours before randomization * Serum potassium ≤ 5.0 mEq/L (mmol/L). * ≤ ½ the optimal dose of ACEi/ARB/ARNi or beta-blocker or MRA. * Written informed consent to participate in the study. Exclusion Criteria: 1. Age below 18 or above 85 years. 2. Clearly documented intolerance to high doses of beta-blockers 3. Clearly documented intolerance to high doses of renin-angiotensin system (RAS) blockers (both ACEi and ARB). 4. Renal disease or estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m2 at screening or history of dialysis. 5. Prior (defined as less than 30 days from screening) or current enrollment in a HF intervention or participation in an investigational drug or device study within the 30 days prior to screening 6. Index event (admission for acute HF) triggered primarily by a completely reversable etiology so that it is unlikely the patient will be classified with chronic HF after discharge, such as Takotsubo syndrome (stress cardiomyopathy). In the setting of acute coronary syndrome or tachycardia, this should be managed before considering the presence of HF. This does not apply to patients with chronic HF prior to the index event. 7. Severe non-adherence to medications 8. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy less than 6 months. 9. History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device. 10. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy. 11. Inability to comply with all study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patients ability to understand and/or comply with the protocol instructions or follow-up procedures. 12. Low digital competency classified as inability to handle a smartphone or tablet. 13. Language barriers requiring the need for an external interpreter. 14. Pregnant or nursing (lactating) women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06576752 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06576752 currently recruiting?
Yes, NCT06576752 is actively recruiting participants. Contact the research team at p.l.myhre@medisin.uio.no for enrollment information.
Where is the NCT06576752 trial being conducted?
This trial is being conducted at Lørenskog, Norway, Drammen, Norway, Arendal, Norway, Ålesund, Norway and 7 additional locations.
Who is sponsoring the NCT06576752 clinical trial?
NCT06576752 is sponsored by University Hospital, Akershus. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.